{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-235819","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2025-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.790606+00:00","generated_at":"2026-05-17T04:09:14.057147+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Agenus enters $10M promissory note with Zydus; bears 3.81% interest, secured by 822,910 INKT shares","bullets":["Up to $10M note at 3.81% p.a.; matures at APA/SPA closing or 10 days after notification that closing will not occur.","Proceeds fund Q4 2025 operational expenses of Emeryville and Berkeley facilities; forgiven if APA/SPA closes.","Collateral: 822,910 shares of MiNK Therapeutics (NASDAQ: INKT); control agreement provides Zydus rights upon default.","Bridge financing tied to pending Zydus asset purchase; facility expense amounts forgiven if deal closes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-235819","json":"https://secwatch.observer/filing/0001193125-25-235819.json","markdown":"https://secwatch.observer/filing/0001193125-25-235819.md","text":"https://secwatch.observer/filing/0001193125-25-235819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000119312525235819/0001193125-25-235819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000119312525235819/agen-20251008.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:09:14.057147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8958273bcb4f18013fbde9ffaad87f934bda1f38","claim":"AGENUS INC incurred loan of up to $10,000,000 with Zydus Pharmaceuticals (USA) Inc. at 3.81% per annum maturing matures upon the closing of the Asset Purchase Agreement and Securities Purchase Agreement signed by Agenus and Zydus on June 3, 2025, or, if such closings will.","evidence_excerpt":"On October 8, 2025, Agenus Inc. (“Agenus”) entered into a Promissory Note Agreement (the “Note”) with Zydus Pharmaceuticals (USA) Inc. (“Zydus”), a wholly owned subsidiary of Zydus Lifesciences Limited, for up to $10,000,000 (the “Principal Amount”). The Note bears interest at 3.81% per annum and matures upon the closing of the Asset Purchase Agreement and Securities Purchase Agreement signed by Agenus and Zydus on June 3, 2025 (together, the “APA/SPA”), or, if such closings will not occur, within 10 days after notification that the APA/SPA closings will not be consummated.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000119312525235819/0001193125-25-235819-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"up to $10,000,000"},{"label":"Counterparty","value":"Zydus Pharmaceuticals (USA) Inc."},{"label":"Rate","value":"3.81% per annum"},{"label":"Maturity","value":"matures upon the closing of the Asset Purchase Agreement and Securities Purchase Agreement signed by Agenus and Zydus on June 3, 2025, or, if such closings will"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}